Cancer Health Disparities - 2010 Conference on The Science of Cancer Health Disparities
Timothy R. Rebbeck, PhD, associate director of population science at the Abramson Cancer Center at the University of Pennsylvania and Editor-in-Chief at AACR's Cancer Epidemiology Biomarkers & Prevention, answers questions about the latest breakthroughs in our understanding of the genetic differences among reaces, trends in cancer health disparities and possible solutions.
Feeling Better Again - Coping with Chemotherapy
This video covers topics such as:
Cellular Vaccine Development as Cancer Therapy
What are cellular vaccines and how do they differ from what we think of as conventional vaccines? What are the various types of approaches that we can potentially use for inducing anti-cancer immunity? Dr. Don Siegel, vice chair and professor of pathology and laboratory medicine at Penn Medicine, talks with host Dr. Lee Freedman about the exciting potential of cellular vaccines as cancer therapy.
Celebrating Innovations 2008: Abramson Cancer Center Research Report and Annual Reception
The Research Report, "Clinical Integration Across Disciplines – Cancer Prevention, Diagnosis, and Cure in Philadelphia" featured the leadership of the Abramson Cancer Center speaking on the clinical integration efforts across disciplines to advance cancer prevention, diagnosis and cure. The three specialty areas highlighted were breast cancer, melanoma, and lung cancer.
Defining Benign vs. Malignant Palpable Masses
When a patient presents with a palpable mass, how can we ensure a proper diagnosis? Is pain often a false gauge of severity? Host Dr. Lee Freedman speaks with Dr. Richard Lackman, professor and chair of orthopaedic surgery and director of the Sarcoma Center of Excellence at the Abramson Cancer Center within the University of Pennsylvania Health System, about treatment modalities for a variety of palpable masses. When should patients be referred to a specialist?
Implementing Proton Therapy for Cancer Treatment
Dr. Stephen Hahn, professor and chair of radiation oncology at the Perelman School of Medicine at the University of Pennsylvania, details advances in our understanding of proton therapy. This innovative cancer treatment could be of great benefit to patients, but, Dr. Hahn cautions, we're still in the early stages of development. Current research must be conducted with the utmost precision. Find out more with host Dr. Lee Freedman.
Molecular Biology and Personalized Cancer Therapy
Dr. Flaherty, a national leader in the understanding of signalling pathways and the molecular biology of cancer, discusses how breakthroughs in understanding intracellular pathways will lead to personalized cancer therapy. Agents such as Sorafenib may be among the first substances that will be used in unique combinations to thwart the growth and spread of malignancies. How will these agents be developed, studied and mixed together for the optimum clinical result? How will the intense research needed for this endeavor be funded? How will the future of cancer treatment be altered?
The Promise of Proton Therapy
Dr. Stephen Hahn, professor and chair of radiation oncology at the Perelman School of Medicine at the University of Pennsylvania, details the basics of proton therapy and provides us with insight on how it may be used to attack cancers. Learn more about the potential of proton therapy to bring new and promising ways to reduce morbidity and side effects. Dr. Lee Freedman hosts.
The Time is Now The Place is Penn Video
The Campaign for Penn Medicine